Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Source: 
Pharmaforum
snippet: 

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of the drug.